Amyloid oligomers, similar to the toxic entities found in Alzheimer's disease patients and in other amyloid-based diseases, are present in cardiomyocytes derived from human heart-failure patients and in animal models of desmin-related cardiomyopathy (DRM). The R120G mutation in ␣-B-crystallin (CryAB) causes DRM and is characterized by aggresomes containing CryAB R120G and amyloid oligomer. In this study, we show that aggresome levels do not correlate with disease. Blocking aggresome formation results in increased levels of toxic amyloid oligomer and decreased cardiomyocyte viability. We confirmed the primary toxicity of intrasarcoplasmic amyloid accumulation in the cardiomyocytes by ectopic expression of the amyloidogenic peptide PQ81, which consists of multiple repeats of a polyglutamine tract. We then addressed the issue of disease reversibility by placing CryAB R120G under inducible cardiomyocyte-specific expression in transgenic mice. The mice developed aggresomes and contained high concentrations of amyloid oligomer in the heart, resulting in cardiac disease. Cessation of CryAB R120G expression in symptomatic mice improved cardiac function and rescued all of the animals from premature death. Rescue was accompanied by significant decreases in amyloid oligomer without a significant reduction in aggresomes. Blocking cardiac amyloid oligomer formation, even after cardiac dysfunction presents, may be a therapeutic strategy in DRM as well as in other types of cardiac disease in which significant amyloid accumulation occurs.
M
any systemic and neurodegenerative disorders whose etiologies are linked to misfolded or unfolded proteins are characterized by the accumulation of intracellular or extracellular protein deposits or aggregates known as aggresomes (1) (2) (3) . Although the pathologies of these diseases are complex, the accumulation of the misfolded and unfolded proteins in the cells is causal for at least some of these neurodegenerative and systemic diseases (4) . Some specific mechanisms have been defined, linking protein-misfolding to decreases in proteasome activity and induction of reactive oxygen species, thus compromising mitochondrial activity (3) . Alterations in the metabolism of the amyloid-␤ (A␤) precursor protein are associated with altered mitochondrial function (5) , and A␤ interacts directly with the A␤-binding alcohol dehydrogenase mitochondrial protein (6) . However, the direct relationship between protein deposition and disease pathology remains controversial. Although protein deposition is associated with neurodegenerative diseases such as Huntington's disease and Alzheimer's disease (7) (8) (9) (10) , there are numerous reports that indicate no correlation or even a negative correlation between deposition and pathology (11) (12) (13) .
Although a relationship between the age-related neurodegenerative diseases and the accumulation of misfolded proteins as amyloid fibrils is recognized, the actual toxic entity remains obscure. In Huntington's disease, expansion of the polyglutamine (PQ) tracts results in large accumulations of aggregates containing these peptides. In Alzheimer's disease, A␤-peptide plaques and misfolded -nuerofibrillar tangles are found, whereas Parkinson's disease is characterized by ␣-synuclein accumulation. Although these and other neurodegenerative diseases involve the accumulation of disparate proteins, they are linked by the accumulation of abnormal aggregates containing a ␤-sheet structure. These ␤-sheet aggregates presumably form because of the protein(s) intrinsic mutation or because of alterations in correct processing, and the assembly pathways themselves have recently become an object of investigation as the prefibrillar intermediates have come under suspicion of being intrinsically toxic (14) . Recent reports suggest that A␤ protein and other amyloidogenic proteins exert their cellular toxicity as soluble amyloidoligomeric intermediates (amyloid oligomer) but not as insoluble aggregates or fibrils (15) (16) (17) (18) . For example, when the small soluble prefibrillar form of A␤ was added to organotypic mouse-brain slice cultures, they acted as potent neurotoxins (19) . Soluble A␤-amyloid oligomers also are found in the cerebrospinal fluid of Alzheimer's disease patients (20) , with the soluble A␤ content of the human brain being a better indicator of disease severity than the content of plaques (21, 22) . The cellular toxicity of soluble amyloid induced by the mutated huntingtin protein, which contains an expanded PQ repeat, also has been linked to the pathogenic cascade of Huntington's disease. Microscopic analysis showed that inclusion-body formation induced by mutant huntingtin was a predictor for improved survival and led to decreased soluble mutant huntingtin levels in neurons, suggesting that inclusion-body formation is actually protective against the toxic mutant protein (23) . These results indicate that the soluble amyloid oligomer may be more important in pathogenesis than the insoluble fibrillar amyloid deposits. An antibody that specifically recognizes a structure of the amyloid oligomer reacts with oligomers generated from all types of amyloidogenic proteins and peptides, such as A␤, ␣-synuclein, PQ, and prions (18) . This result implies that the amyloid oligomer has a shared structure between diverse proteins and also may share a common mechanism of pathogenic action.
The R120G missense mutation in the small heat-shock protein ␣-B-crystallin (CryAB) causes desmin-related cardiomyopathy (DRM) (24) . DRM, which is characterized by the formation of aggregates containing CryAB and desmin, can be recapitulated in transgenic (TG) mice by expression of the mutant protein specifically in the heart (25) . We showed that CryAB R120G led to perinuclear aggresome formation and that these aggresomes This paper was submitted directly (Track II) to the PNAS office.
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contained amyloid oligomer, suggesting that CryAB-DRM is a subclass of the aggresomal and amyloid-related diseases (26) . These mice invariably developed heart failure and exhibited 100% mortality by 5-7 months. Somewhat surprisingly, the amyloid oligomer also was present in cardiomyocytes derived from multiple human dilated and hypertrophic cardiomyopathies, indicating that intrasarcoplasmic amyloidosis might be a prevalent contributor to cardiac disease (26) .
In this study, we characterize the molecular basis of the cardiac pathology by analyzing the relationships between aggresomes, oligomeric amyloid formation, cardiac function, and survival in CryAB R120G -DRM in vitro as well as in an inducible TG mouse model in which CryAB R120G can be reversibly expressed or suppressed specifically in cardiomyocytes. Inducible CryAB R120G expression led to the accumulation of CryAB-positive aggregates that contained the amyloid oligomer, with the mice showing cardiac dysfunction and premature death by heart failure. Deinduction of CryAB R120G expression in symptomatic mice Ϸ2-3 weeks before death had no significant effect on aggresome levels. However, cessation of CryAB R120G expression resulted in improved cardiac function, prevention of death, and decreases in cardiomyocyte amyloid.
Materials and Methods TG Mice. Male FVB͞N mice with cardiac-specific overexpression of CryAB WT or CryAB R120G driven by the ␣-myosin heavy-chain promoter were described in ref. 25 . To generate mice with cardiac-specific inducible overexpression of CryAB R120G , the CryAB R120G cDNA was inserted into a modified myosinpromoter cassette as described in ref. 27 . The responder CryAB R120G mice were crossed with tetracycline-controlled transcriptional activator (tTA) mice to generate the tTA͞ CryAB R120G double-TG mice.
Cardiomyocyte Cultures and Adenovirus Infection. After isolation of rat neonatal cardiomyocytes (RNCs), cells were grown in twowell chambered glass slides coated with gelatin. Replicationdeficient recombinant adenoviruses were made by using the AdEasy system (Stratagene) (28) . cDNAs were isolated by using RT-PCR and were used to generate adenoviral constructs as described in ref. 26 . Constructs containing the expanded PQ fragment were provided by James R. Burke (Duke University, Durham, NC). A hemagglutinin epitope (HA) at the carboxyl terminus of the PQ was added, and the DNA was used to generate adenovirus constructs (29) . The cells were normally transfected at a multiplicity of infection of 10 for each virus, except where indicated. To distinguish the TG products from the endogenous CryAB protein, a FLAG-epitope was introduced at the N termini of CryAB WT and CryAB R120G . The filter assay for detection of aggregates was performed as described in ref. 30 . The aggregate fraction on the membrane was detected with anti-CryAB or anti-HA.
Echocardiography. Echocardiography was performed on isoflurane-anesthetized animals by using a Sonos 5500 ultrasound system (Hewlett-Packard) equipped with a 12-MHz transducer. Two-dimensionally guided M-mode echocardiography of the left ventricle from its short axis was recorded on an optical disk and a strip chart at a speed of 100 mm͞s.
Immunohistochemistry. Immunohistochemical analyses were performed as described in refs. 25 and 26. Cell culture media were from Life Technologies (Grand Island, NY). Alexa Fluor 488-conjugated anti-rabbit and Alexa Fluor 568-conjugated antimouse antibodies, phalloidin-Alexa Fluor 594, and TO-PRO-3 for nuclear staining were from Molecular Probes. Anti-CryAB antibody (SPA-223) and anti-HSP25 (SPA-801) were from Stressgen Biotechnologies (Victoria, Canada), anti-FLAG was from Stratagene, and anti-HSP70 (W27) and anti-HA (Y11) were from Santa Cruz Biotechnology. Anti-cTnI antibody (MAB1691) was from Chemicon International (Temecula, CA). Anti-amyloid oligomer antibody either was made by using a micelle molecular mimic of soluble A␤ oligomer (18) or was purchased from BioSource International (Camarillo, CA), and anti-myc tag antibody was from Invitrogen. Cellular toxicity was analyzed 5 days after transfection by measuring the release of adenylate kinase from damaged cells into the culture media by using the ToxiLight assay (Cambrex, East Rutherford, NJ). METAMORPH software (version 6.3, Universal Imaging, Media, PA) was used to quantitate immunofluorescent intensity. Histograms depicting the number of pixels vs. signal intensity were constructed by using the histogram function. Average signal intensity was defined by using the threshold function. The area stained with oligomer antibody was defined, and the average pixel intensity of the selected regions was recorded for comparison.
Results

Aggresomes, Amyloids, and Cytotoxicity in CryAB R120G -Transfected
Cardiomyocytes. Aggresomal formation is associated with many pathologies, but whether it is a protective or cytotoxic mechanism remains controversial (31) . Although there is a common pathway of aggresome formation, their composition and structure depends upon the aggregating substrate as well as the cell type, and aggresomes may be cytoprotective in some cells (23) but pathogenic in others. We explored the potential cytotoxicity of the aggresomes by using RNCs. Amyloid oligomer was undetectable in untreated cardiomyocytes and barely detectable in CryAB WT -transfected myocytes (Fig. 1A) . In contrast with these data, when CryAB R120G was expressed at equivalent levels (Fig. 1B Upper) in the transfected cardiomyocytes, perinuclear aggresomes were apparent, and these were stained intensely for both CryAB and amyloid oligomer (Fig. 1 A) . To determine whether increasing the level of chaperone-competent CryAB decreased aggresome formation, we performed a series of cotransfections with CryAB WT and CryAB R120G . Cotransfection of CryAB R120G with CryAB WT led to equal levels of expression for each (Fig. 1B) and resulted in a diffuse pattern of staining in which large, perinuclear CryAB-positive aggregates were reduced. However, the amyloid oligomer remained distributed throughout the cytoplasm with overall levels increased ( Fig. 1 A,  D , and E). Cotransfection and expression of CryAB WT led to a significant decrease in aggresomal accumulation ( Fig. 1 B and  C) . Quantitation of amyloid accumulation showed that the fraction of cytoplasm occupied by amyloid oligomer-positive material more than doubled, with a striking increase in the signal intensity ( Fig. 1 D and E) . Strikingly, decreased aggresomal formation and enhanced amyloid oligomer formation led to a significant increase in cytotoxicity (Fig. 1F) . The apparent decrease in aggresomal accumulation, accompanied by decreased cell viability, implies that aggresome accumulation may be cytoprotective by lowering levels of the toxic amyloid oligomer in cardiomyocytes.
Supporting the commonality of the toxic oligomer hypothesis for amyloid-based disease is the observation that several distinct amyloidogenic proteins, including CryAB R120G , A␤, ␣-synuclein, and PQ-expansion proteins, share an epitope that is recognized by an oligomer-specific antibody (18, 32) . To understand whether the cardiomyocyte CryAB R120G data could be extended to other amyloidogenic proteins, we analyzed the consequences of expressing a peptide containing 81 repeats of glutamine (PQ81), which is known to cause Huntington's disease (33) . A nonamyloidogenic peptide containing PQ19 was used as a negative control. Cardiomyocytes transfected with PQ81 showed PQ-positive aggresomes in the cytoplasm, whereas no aggre- somes were observed in myocytes transfected with PQ19 ( Fig.  2A) . Again, when increased levels of chaperone-competent CryAB were achieved by means of cotransfection with CryA-B WT , aggresome levels were reduced, compared with PQ81-transfected cells (Fig. 2 B and C) , mimicking the cotransfections carried out with CryAB R120G and CryAB WT . CryAB WT inhibits PQ-aggresome formation, presumably by blocking polymerization (34) .
In contrast with the effects of cotransfection on aggresome accumulation, the presence of increased amounts of CryAB WT resulted in higher levels of amyloid oligomer (Fig. 3 A-C) and increased cytotoxicity in the PQ81-transfected myocytes (Fig.  3D) . Thus, in the presence of a primary stimulus that leads to toxic amyloid oligomer accumulations in the cardiomyocytes, decreased aggresome levels are associated with increased amyloid levels and a relative decrease in viability.
Reversibility of Amyloidosis in Vivo.
We have modeled CryAB R120G DRM in vivo by using cardiac-specific transgenesis (25, 26) . CryAB R120G expression leads to the formation of protoaggresomes and amyloid accumulation within about 5 days. As the mice age, aggresomes and amyloid oligomer levels increase, and the mice die of heart failure between 5 and 7 months. We wished to determine whether amyloid formation was reversible and created a cardiac-specific inducible model of CryAB R120G DRM by using the tTA system (''tet-off'') and inducible ␣-myosin heavy-chain promoter construct (27) . The bigenic mice showed tight regulation of CryAB R120G , with no detectable expression in the presence of doxycycline (DOX) and expression at or above the levels observed for a standard TG line (line 134) when the drug was removed (Fig. 4A) . After 6 weeks, atrial natriuretic factor, a sensitive stress marker in the adult heart, is significantly elevated in both the standard and induced TG lines. DOX treatment reversibly shut down transgene expression and largely attenuated atrial natriuretic factor up-regulation (Fig. 4A) . Thus, we can reversibly regulate CryAB R120G expression with DOX treatment in the tTA͞CryAB R120G double-TG mice. Mice were allowed to express CryAB R120G , and cardiac func- tion was determined by echocardiography. At 9 weeks, the shortening fractions of the double-TGs were indistinguishable from those of controls. However, by 11-12 weeks, the mice showed a reduction in fractional shortening that became more severe until death at Ϸ15-16 weeks (Fig. 4 B and C) . Mice in which the transgene was not inactivated went into acute failure between 3.5 and 4 months, with visible signs of heart failure characteristic of the standard CryAB R120G line, including failure to groom, listless cage behavior, edema, and ascites fluid in the body cavity upon postmortem inspection. DOX treatment started at 12 weeks dramatically improved shortening fractions in the symptomatic double-TG mice, rescuing them from premature death (Fig. 4 B and C) . Animals kept on DOX have survived until killed 1-3 months later, with no visible signs of distress, ascites fluid, or pulmonary congestion.
The mice were killed at 15-16 weeks, and immunohistology and biochemical analyses were performed. The left ventricular weight͞body weight of non-TG (NTG) mice with or without DOX was 3.2 Ϯ 0.02 mg͞g and 3.1 Ϯ 0.01 mg͞g, respectively, and the left ventricular weight͞body weight of the double-TG mice with or without DOX was 4.5 Ϯ 0.04 mg͞g and 4.4 Ϯ 0.06 mg͞g, respectively. The double-TG mice showed cardiac hypertrophy that was not completely attenuated by DOX treatment, even though normal shortening fractions were recovered. The double-TG mouse hearts contained massive accumulations of CryAB-positive aggresomes in the cardiomyocytes (Fig. 5 A and  B) . DOX treatment started at 12 weeks did not have an effect on aggresome levels (Fig. 5 C and D) . In contrast with the aggresomes, levels of the amyloid oligomer were dramatically reduced in the animals that were treated at 12 weeks after significant amyloid accumulations had developed (Fig. 6) . The in vivo data are consistent with the lack of cytotoxicity for the aggresomes and the correspondence of disease with elevated amyloid oligomer levels.
Discussion
A primary goal of this study was to understand whether cardiomyocyte aggresome accumulation was intrinsically pathogenic. Amyloid oligomer in PQ81-transfected myocytes. Cardiomyocytes were identified by TnI staining (green). Amyloid oligomer (red) was observed in aggregates that formed as a result of PQ81 expression. Although visible aggregates cannot be observed in the cultures that were cotransfected with CryAB WT (CryAB), amyloid oligomer levels were significantly increased. Nuclei (blue) were stained by TO-PRO-3. (B and C) Quantitative analysis of amyloid oligomer. Average amyloid oligomer intensity (B) and intensity distributions (C) were determined in PQ81-or PQ19-transfected myocytes with or without CryAB WT cotransfection. (D) Cellular toxicity was measured by the release of adenylate kinase into the medium. Values shown are the -fold increase relative to uninfected cardiomyocyte cultures, whose value was set to 1. ** , P Ͻ 0.01; *** , P Ͻ 0.001 vs. LacZ-transfected myocytes (LacZ); #, P Ͻ 0.05 vs.
PQ81-transfected myocytes (PQ81); a, P Ͻ 0.05 vs. CryAB R120G -transfected myocytes (R120G). CTL, untreated cardiomyocytes. We also wished to determine the ability of the heart to clear the amyloid or aggresomes and subsequently recover from aggresome-or amyloid-induced disease if the primary stimulus could be ablated or blocked. It has been hypothesized that aggresome formation as a result of CryAB R120G expression was pathogenic, and that delay of aggresomal formation by expression of CryAB WT would delay the onset of the disease (35) . Our data show that inhibition of aggresome formation is associated with increased cytotoxicity and correlates with an increase in amyloid oligomer-positive material. The data are consistent with the hypothesis that inclusion-body formation in this disease sequesters amyloidogenic protein from the general cytoplasm, with a net effect of decreasing the risk of cell death. In general, chaperones such as CryAB may participate in a number of cellular processes, helping to modulate correct protein-folding, compartment-targeting, degradation, and signaling processes. These actions can suppress aggregation, and CryAB's behavior in the cardiomyocyte is consistent with its participation in these processes.
Many of the neurodegenerative diseases exhibit increasing accumulations of distinct aggregated proteins that, although unrelated in their primary amino acid sequences, form characteristic amyloid-like fibrils. A continuing controversy in these pathologies is the role that these aggregates play and whether the fibrillar state of the various aggregated disease proteins is protective, pathogenic, or irrelevant to the developing disease process. Amyloid oligomer levels showed a positive correlation with cellular toxicity in the transfected cardiomyocytes. The direct effect of the amyloid oligomer on cardiomyocyte toxicity was confirmed by ectopic expression using the expanded PQ81 and suggests that, in cardiomyocytes, toxicity of the soluble amyloid oligomer is independent of the protein species. Our findings concerning the common pathology of the amyloid intermediate as a result of either CryAB R120G or PQ81 expression are consistent with the hypothesis that a common structure of soluble nonfibrillar intermediates exists for different amyloidogenic molecules, resulting in common pathogenic mechanisms for widely varying primary etiologies (18, 26) .
In our system, CryAB is not cytoprotective when the cardiomyocyte is challenged with either CryAB R120G or PQ81, although it did prevent inclusion-body formation. The data suggest that, in the isolated cardiomyocyte, at least some chaperones can enhance amyloid oligomer levels by inhibiting aggregate formation. In contrast with these data, a number of in vitro studies showed that overexpression of heat-shock protein family members significantly attenuated A␤-, PQ-, and ␣-synucleinmediated toxicity (3), indicating that chaperone expression was cytoprotective against neurodegeneration. In fact, a number of genetic studies in animal models of human disease indicate that molecular chaperones are potent suppressors of neurodegeneration (36) (37) (38) . The mechanism or mechanisms have not been defined, but a reasonable hypothesis is that the chaperone might decrease initial formation of the soluble but misfolded protein supramolecular structures that go on to develop amyloid-like characteristics. In fact, treatment of animal models of Parkinson's disease, amyotrophic lateral sclerosis, or surgically induced neuronal degeneration, either with small molecules that induce heat-shock protein synthesis or with heat-shock proteins directly, can be neuroprotective and has been proposed as a treatment in some patients suffering from these diseases (3, 36) . We think it likely that experimental outcome is dependent on the class of heat-shock protein expressed as well as the cell type. For example, in cell culture, rather than protecting neurons from A␤1-40 toxicity, CryAB expression actually increased toxicity (39) . With respect to cardiac disease, it appears that CryAB expression, while ablating fibril or aggresome formation, promotes the formation of the toxic oligomer, at least in the cardiomyocyte cultures.
It is well established for the neurodegenerative diseases that aberrant protein-folding can result in intracellular or extracellular aggregate accumulations and subsequent amyloid formation (3). The R120G mutation significantly impacts on CryAB's ability to act as a chaperone (35), thus partially explaining the formation of large aggregates. Our data show that preventing aggresome formation in cardiomyocyte cultures by increased chaperone expression leads to increased levels of amyloid oligomer and increased cell death. These data, although not proving that cardiomyocyte aggresomes are cytoprotective, are consistent with the role of inclusion bodies in Huntington's disease, in which their formation rendered the neuron more likely to survive (23) .
Reversibility of CryAB R120G Cardiac Disease. Aggregate formation by unfolded or misfolded proteins has been thought of as one of the typical pathologies in many degenerative diseases (3, 4) . As previously shown by using the ␣-myosin heavy-chain promoter to drive cardiac-specific expression of CryAB R120G , CryAB R120G accumulation recapitulates DRM pathology, resulting in eventual heart failure and death. In the studies outlined above, it became apparent that amyloid oligomer levels were correlated with increased cytotoxicity. We, therefore, examined whether, in vivo after heart disease presented, amyloid levels could be decreased, and whether those decreases correlated with functional recovery. Abrogation of CryAB R120G expression only a short time before death had a striking effect on preventing mortality: mouse viability was invariably linked to decreased amyloid oligomer levels, with little or no decrease in the aggresomes. Because we have determined that amyloid formation in cardiomyocytes appears to be common in heart failure patients (26) , our experiments underscore the potential feasibility of a partial reversal of amyloid-induced pathology in many cardiovascular diseases if the endogenous clearance pathways that are present in the cardiomyocyte can be defined and regulated, or if effective pharmacologic means for amyloid clearance can be found.
